Early- Versus Late-Onset Type 1 Diabetes: Two Different Pathophysiological Subtypes with Implications for Therapy by Kühtreiber, Willem M. et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 3
Early- Versus Late-Onset Type 1 Diabetes: Two
Different Pathophysiological Subtypes with
Implications for Therapy
Willem M. Kühtreiber, Miriam Davis and
Denise L. Faustman
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/65598
Provisional chapter
Early- Versus Late-Onset Type 1 Diabetes: Two Different
Pathophysiological Subtypes with Implications for
Therapy
Willem M. Kühtreiber, Miriam Davis and
Denise L. Faustman
Additional information is available at the end of the chapter
Abstract
Insulin, as measured by C-peptide, is produced for decades after onset of type 1 diabetes,
and even very low levels of C-peptide have clinical significance. In this chapter we show
that two distinct pathophysiological subtypes of type 1 diabetic subjects can be
distinguished. Early-onset diabetic subjects (≤20 years) have rapid loss of C-peptide,
whereas late-onset diabetic subjects (>20 years) have slower C-peptide declines over
decades. Early-onset diabetics have significantly lower levels of persistent autoreactive
CD8+ T cells than do late-onset diabetic subjects. In late-onset disease, robust production
of autoreactive T-cells occurs even in the absence of C-peptide. Metabolomics analysis
reveals frequent differences between the two subtypes of subjects in the levels of amino
acids, carbohydrates, cofactors, lipids, peptides, and xenobiotics. There are statistically
significant differences related to protective islet functions, islet health, development,
blood sugar control, and regulation of exocrine pancreas function. Taken together these
findings suggest that pancreas pathobiology, as well as durability of abnormal T-cell
response should be considered in immune targeting treatments. Therapies aimed at
immune defects alone are likely to work best in late-onset diabetics. Therapies aimed at
islet cell preservation in early-onset diabetic subjects likely have greater efficacy if
administered shortly after disease onset.
Keywords: type 1 diabetes, C-peptide, metabolomics, autoreactive T-cells, therapy,
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1. Introduction
This chapter summarizes the evidence supporting two distinct pathophysiological subtypes
of type 1 diabetes (T1D) based on age of onset (AOO). The characterization of these two
subtypes—early- versus late-onset—traces back to the finding that β-islet cells of the pancreas
are still functional decades after disease onset. When first published in 2012 [1], this finding
ran against conventional wisdom that all beta cells die within 2 years of onset and that type 1
diabetics usually have an absolute deficiency of insulin [2]. Instead, low levels of C-peptide,
which is co-secreted with insulin and thus serves as the best measure of endogenous insulin
secretion, persist for decades after disease onset. Confirmation of the study by Wang and
colleagues came from several studies [3–8], showing that 80% of people with long-standing
diabetes have low but detectable levels of C-peptide upon stimulation with oral glucose [9].
These studies were made possible by new ultrasensitive C-peptide assays with detection limits
of 1.5–5.0 pmol/L. Older C-peptide assay typically only detected to 40–50 pmol/L. The low
levels of C-peptide were indicative of intact β-islet cell function according to assays showing
that C-peptide levels rose in response to hyperglycemia or a mixed-meal stimulus [1, 4, 5].
Intact β-islet cell function in long-standing disease suggests that β-islet cells are either
regenerating or evading immune attack.
What’s more is that these low levels of C-peptide or any persistent C-peptide have clinical
significance. They are associated with fewer diabetic complications (e.g., nephropathy, neu-
ropathy, foot ulcers, and retinopathy), better metabolic control via HbA1c, and prevention of
hypoglycemia [7, 10–12]. The finding of C-peptide persistence and its clinical significance
paved the way for an examination of the pathophysiological differences between early- and
late-onset type 1 diabetes.
2. Rate of C-peptide decline differs between early- and late-onset
diabetes
Early-onset diabetics have a rapid loss of residual C-peptide, whereas late-onset diabet-
ics have a slower rate of C-peptide decline, which occurs over decades [1, 6, 8].  Here,
we confirm this finding with one of the largest patient samples to date of fasting C-
peptides.
Cross-sectional data from 1958 long-term type 1 diabetics, who were recruited to the Massa-
chusetts General Hospital, show the gradual decades-long decline in fasting C-peptide
secretion from the pancreatic islets (Figure 1A). The rate of decline in this group varied
according to age of onset, with early-onset diabetics (n = 1063) showing a rapid decline and
late-onset (n = 895) showing a slow decline (Figure 1B, left and right panels). The difference in
C-peptide secretion between early-onset and late-onset subjects is statistically significant (p <
0.001). Detecting low fasting C-peptide levels during the decades-long decay is possible
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because of the improved detection limit with ultrasensitive ELISA1 of only 1.5 pmol/L, which
is significantly lower than older C-peptide assays with detection limits in the 40–50 pmol/L
range [1]. The remainder of the chapter delves into the pathophysiological basis of this finding,
using an assay for autoreactive CD8+ T lymphocytes (hereinafter referred to as autoreactive
T-cells) and using metabolomics, the study of small molecules from intermediate metabolism.
1 Cat. No 10-1141-01, Mercodia AB (Uppsala, Sweden). The assay was calibrated against the International Reference
Reagent for C-peptide (IRR C-peptide 84/510; a WHO standard) and listed with the US Food and Drug Administration
as Class I IVD device.
Figure 1. The decades-long persistence of C-peptide in patients with type 1 diabetes (n = 1958) and the more rapid fall
in C-peptide levels with younger age of onset. (A) There is a gradual, decade-long decline in C-peptide detectable with
an ultrasensitive assay. (B) The decline in C-peptide levels is related to the age of onset of the disease. Data are strati-
fied by early- (left, blue) or late-onset diabetes (right, red). p Values were calculated using a Mann-Whitney U test (Wil-
coxon rank-sum test), and the data are represented as mean ± SEM p < 0.001. The left panel depicts the large difference
in mean C-peptide, whereas the right panel shows the same data according to individual data points.
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3. Levels of autoreactive T-cells differ between early- and late-onset
diabetes
Here, we provide evidence that early-onset diabetics (≤20 years of age) have a significantly
lower level of autoreactive T-cells than do late-onset diabetics (>20 years of age). We studied
autoreactive T-cells in a subset (n = 178) of our sample (n = 1958) using a peptide-major
histocompatibility complex class I (pMHC-I) multimer technique (fluorochrome-conjugated
and peptide-loaded major histocompatibility complex class I multimers) in conjunction with
flow cytometry. Two diabetes-specific peptides for autoreactive T-cell detection were used, i.e.,
peptide sequences from epitopes of pancreatic beta cells, islet-specific glucose-6-phosphatase
catalytic subunit-related protein (IGRP) or insulin B chain (InsB) (tetramers were purchased
from Beckman Coulter, Fullerton, CA, whereas dextramers were a generous gift from Immu-
dex, Copenhagen, Denmark). For the IGRP peptide, pMHC-I was loaded with the peptide
sequence for amino acids 228–236 (LNIDLLWSV). For the InsB peptide, pMHC-I was loaded
with the peptide sequence corresponding to amino acids 10–18 (HLVEALYLV). For back-
ground fluorescence of T-cells, a matched negative (neg) HLA class I structure was loaded with
an irrelevant peptide. The peptide sequence of the negative controls is kept proprietary by the
companies but does not occur on mammalian cells (Beckman Coulter, Immudex). Using these
methods, type 1 diabetics for decades after diagnosis have detectable levels of autoreactive T-
cells measured with peptide-major histocompatibility complex class I (pMHC-I) multimers
(Figure 2).
Type 1 diabetics were cross-sectionally studied for the presence or absence of autoreactive T-
cells for decades after disease onset. The patients all had established type 1 diabetes (Table 1).
Subjects had mean age of onset of 27.9 ± 1.6 years and a mean duration of diabetes of 14.9 ± 1.4
years. Typically, autoreactive T-cell detection studies are performed shortly after disease onset.
However, because we wanted to know the association between prolonged C-peptide secretion
and autoreactive T-cells, this study spanned decades of diabetes duration with simultaneous
monitoring of C-peptide. Autoreactive T-cells were defined as samples staining with either
IGRP or InsB MHC class I multimers. The data show that some long-standing diabetics have
persistence of autoreactive T-cells decades after disease onset.
The type 1 diabetic subjects studied for autoreactive T-cells with pMHC-I multimers were
divided into two groups, based on their status of early onset (n = 131, shown in blue) or late
onset (n = 47), shown in red (Figures 3 and 4, Table 1). For each group, we determined the
disease duration versus the serum C-peptide levels (Figure 3A). For each group, we also
determined the presence of autoreactive T-cells versus disease duration (Figure 4). We once
again observed that the decay of C-peptide secretion is faster in the early-onset group as
compared to the late-onset group. For most subjects with early-onset, the C-peptide became
undetectable within 10 years, whereas in the late-onset subjects, C-peptide lingered for
decades (Figure 3A). The difference in C-peptide between the early-onset and late-onset was
highly significant (C-peptide for early-onset 33.9 ± 5.4 pmol/L versus C-peptide for late-onset
98.6 ± 13.5 pmol/L (mean ± SEM; one-tailed Mann-Whitney U test p < 0.0001)).
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Figure 2. Type 1 diabetics for decades after diagnosis have detectable levels of autoreactive T-cells measured with pep-
tide-major histocompatibility complex I (pMHC-I) multimers. Both insulin B and IGRP pMHC-I multimers were able
to detect autoreactive CD8 T-cells of long-term diabetics. n = 192 samples for negative controls and n = 178 for samples
stained for autoreactive cells. The means are represented by the large red dots. The background of 0.24% positive back-
ground fluorescence was used as the lower limits of detectability for the presence of pMHC-I multimers. Mann-Whit-
ney U test shows a significant difference at p = 0.02.
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All Early Late
n 178 47 131
AOO (years) 27.9 ± 1.6 10.7 ± 1.2 34.7 ± 1.1
Duration (years) 14.9 ± 1.4 22.0 ± 2.6 11.3 ± 1.3
% Female 42.0% 46.2% 40.5%
C-peptide (pmol/L) 47.6 ± 14.3 3.8 ± 1.3 78.8 ± 18.9
Gad65 Ab (U/mL) 93.0 ± 12.0 84.7 ± 26.5 95.5 ± 13.5
All values are mean ± SEM.
Table 1. Clinical characteristics for early- and late-onset T1D.
Figure 3. Early- and late-onset type 1 diabetics not only vary in the persistence of C-peptide but also dramatically vary
by the presence or absence of autoreactive T-cells. (A) For this data set of early-onset diabetics (n = 47) and late-onset
diabetics (n = 131), C-peptide decay continues to show prolonged presence exclusively in late-onset diabetes. (B) Late-
onset diabetics have persistence of C-peptide and also the presence of abundant autoreactive T-cells. Early-onset dia-
betics have neither the persistence of C-peptide nor the presence of autoreactive cells. (C) At undetectable C-peptide
levels in an ultrasensitive assay almost no autoreactive T-cells are detectable in early-onset subjects, but abundant au-
toreactive T-cells are present in late-onset diabetics. Mann-Whitney U test, p = 0.0005.
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Figure 4. Relationship of diabetes disease duration and presence of autoreactive T-cells; comparison of early- and late-
onset diabetes.
We then determined the levels of autoreactive T-cells in the early- and late-onset diabetic
subjects using the pMHC-I multimer technique (Figure 3B and C). The early-onset group had
little or no detectable C-peptide and little to no autoreactive T-cells. In contrast, the late-onset
group frequently had large amounts of C-peptide coupled with large numbers of autoreactive
T-cells. At first glance this seemed to make sense since the presence of islet activity in the
pancreas is expected to be associated with the persistence of active CD8 autoimmunity. Also
when we studied early- and late-onset subject pMHC-I autoreactive T-cells compared to
disease duration, the early-onset diabetics had no relationship with duration and the presence
or absence of T-cells. In contrast, late-onset diabetics had a decades-long decay in the presence
of autoreactive T-cells (Figure 4).
But when early- and late-onset diabetics were compared when neither group had any detect-
able C-peptide, the late-onset diabetic subjects still continued to exhibit the abundant presence
of autoreactive T-cells (Figure 3B and C, p = 0.0005). In marked contrast, when the early-onset
diabetics were without detectable C-peptide, even when using an ultrasensitive C-peptide
assay, almost no autoreactive T-cells were found in the early-onset cohorts. What are the
possible explanations?
Our favored explanation is that autoreactive T-cells play a much more dominant role in disease
etiology in late-onset than in early-onset disease. The massive abundance of detectable
autoreactive T-cells in late-onset diabetics even without detectable C-peptide may reflect
greater regenerative abilities of the pancreas, causing autoreactive T-cells to remain in the
circulation. A trivial second explanation is that the two types of autoreactive T-cells measured,
i.e., InsB and IGRP autoreactive T-cells, represent the dominant autoreactive epitopes in late-
onset disease, but not in early-onset disease. Although C-peptide can now be detected to 1.5
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pmol/L, this assay might still not be sensitive enough, and the T-cell assay is more sensitive
for residual pancreatic activity, and that would also be an explanation for long-term autoreac-
tive T-cells in late-onset diabetic subjects.
Why such non-detectable levels of autoreactive T-cells in early-onset diabetics? Primary
pancreas defects unrelated to autoreactive T-cells may contribute to more rapid pancreatic islet
failure in early-onset diabetics. The role of autoreactive T-cells may be less dominant in early-
onset cases. Or as above, these early-onset diabetic subjects truly have no C-peptide and levels
far below the sensitive assay levels of new C-peptide assays of 1.5 pmol/L.
4. Metabolomics differ between early- and late-onset diabetes
We studied metabolites in the serum of early-onset versus late-onset diabetics that might shed
light on disease pathophysiology. Metabolomics was performed on two independently
collected subject serum sets, referred to as serum set 1 and serum set 2, in order to verify
findings. The subjects were two matched sets with 25 early- and 25 late-onset diabetic subjects
with HbA1Cs in the same range. A total of 100 frozen serum samples were analyzed. The
samples were sent for metabolic profiling to Metabolon (Durham, NC). Samples were extracted
and prepared for analysis on Metabolon’s integrated discovery platform that was based on a
combination of gas and liquid chromatography techniques coupled with mass spectrometry
for detection and identification. Metabolon’s platform has met with considerable success in,
among many studies, the identification of biomarkers of insulin resistance in subjects that are
at risk of developing type 2 diabetes [13].
The clinical and biochemical characteristics of each serum set are shown in Table 2. The patient
selections for each sample set were limited to subjects with disease duration of less than 25
years and a current age of less than 50 years to exclude kidney disease and other confounding
factors in metabolism. We then statistically compared the data from early- versus late-onset
diabetics and report only on those metabolites that were significantly different across both
screens.
AOO (years) Age (years) Duration (years) C-peptide (pmol/mL) HbA1C (%) Female (%)
Serum set 1
Early-onset 9.8 ± 0.7 23.3 ± 1.5 9.5 ± 1.2 40.5 ± 18.5 8.2 ± 0.4 32.0
Late-onset 35.8 ± 2.0 48.6 ± 2.3 8.4 ± 1.0 117.5 ± 43.5 7.2 ± 0.2 44.0
Serum set 2
Early-onset 10.2 ± 0.7 16.8 ± 0.9 5.7 ± 0.9 87.9 ± 29.8 7.5 ± 0.2 36.0
Late-onset 32.8 ± 2.5 41.5 ± 2.3 7.7 ± 1.1 152.5 ± 50.6 6.7 ± 0.2 44.0
All values are mean ± SEM.
Table 2. Clinical characteristics of early- and late-onset diabetics for metabolomic assays .
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Table 3 lists 30 metabolites that display statistically significant differences between early-onset
and late-onset type 1 diabetes from both serum set 1 and serum set 2. These metabolites are
found in diverse super pathway families, including amino acids, carbohydrates, cofactors and
vitamins, lipids, peptides, and xenobiotics. Table 3 also lists the subpathways. Figure 5 graphs
the same data according to the fold differences and also the direction, i.e., early- < late-onset
or early- > late-onset. The data show that the fold differences were extremely similar for serum
set 1 subjects and serum set 2 subjects and always in the same direction. The data trends were
remarkably reproducible given that these were independently collected human samples.
Metabolite Super pathway Subpathway  p
Serum set 1 
p
Serum set 2
Creatinine Amino acid Creatine metabolism 0.0206 0.034
N-acetyl-3-methylhistidine Amino acid Histidine metabolism 0.0018 0.0441
3-methylglutaconate Amino acid Leucine, isoleucine, and valine
metabolism
0.0049 0.0216
N2-acetyllysine Amino acid Lysine metabolism 0.0429 0.0334
N-acetylphenylalanine Amino acid Phenylalanine and tyrosine metabolism 0.0092 0.0345
Spermidine Amino acid Polyamine metabolism 0.0458 0.0224
N-acetyltryptophan Amino acid Tryptophan metabolism 0.001 0.036
Pro-hydroxy-pro Amino acid Urea cycle: arginine and proline
metabolism
1.06E−05 2.81E−09
Trans-4-hydroxyproline Amino acid Urea cycle: arginine and proline
metabolism
0.001 3.00E−04
Glucuronate Carbohydrate Amino sugar metabolism 0.025 3.34E−08
Sucrose Carbohydrate Disaccharides and oligosaccharides 0.007 4.00E−04
Fructose Carbohydrate Fructose, mannose, and galactose
metabolism
0.020 0.003
Sorbitol Carbohydrate Fructose, mannose, and galactose
metabolism
0.001 0.001
Glucose Carbohydrate Glycolysis, gluconeogenesis, and
pyruvate metabolism
0.003 0.044
Ascorbate (vitamin C) Cofactors and
vitamins
Ascorbate and aldarate metabolism 0.018 0.012
Trigonelline (N′-
methylnicotinate)
Cofactors and
vitamins
Nicotinate and nicotinamide
metabolism 
0.005 1.40E−06
Alpha-tocopherol (vitamin E) Cofactors and
vitamins
Tocopherol metabolism 0.001 0.002
Pyridoxate (vitamin B6) Cofactors and Vitamin B6 metabolism 0.002 0.014
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Metabolite Super pathway Subpathway  p
Serum set 1 
p
Serum set 2
vitamins
CMPF Lipid Fatty acid, dicarboxylate 0.000 0.001
Eicosapentaenoate (EPA) Lipid Polyunsaturated fatty acid (n3 and n6) 2.00E−04 0.002
Hyocholate Lipid Secondary bile acid metabolism 0.001 0.023
Taurodeoxycholate Lipid Secondary bile acid metabolism 0.011 0.047
Etiocholanolone glucuronide Lipid Steroid 0.021 0.002
Cholesterol Lipid Sterol 0.014 0.009
Leucylglycine Peptide Dipeptide 0.003 0.012
Valylglycine Peptide Dipeptide 0.001 2.75E−07
1,3-dimethylurate Xenobiotics Xanthine metabolism 0.010 0.004
1,3,7-trimethylurate Xenobiotics Xanthine metabolism 0.020 0.001
1,7-dimethylurate Xenobiotics Xanthine metabolism 0.024 0.009
Paraxanthine Xenobiotics Xanthine metabolism 0.032 0.007
Table 3. Early- versus late-onset T1D: metabolites with significant differences.
A subset of 7 out of 30 metabolites is important and is involved in pancreatic function (Table 4).
In all cases, the pancreas-related metabolites were statistically different between early-onset
and late-onset diabetic subjects.
Subjects with early- versus late-onset diabetes have varying levels of acetyllysine. Developing
and proliferating insulin-secreting β-islet cells have augmented acetyltransferase activity
related to growth and insulin secretion often through beta-cell–specific transcription factors
BETA2 and PDX-1. High lysine deacetylase activity would be expected to increase the removal
of acetyl groups from proteins. In our data the early-onset diabetics had lower levels of
acetyllysine. Lysine deacetylase inhibitors protect β-islet cells by increasing the acetylation of
proteins. In support of our observations, treatment data from the nonobese diabetic (NOD)
mouse, an animal model of type 1 diabetes, shows that lysine deacetylase inhibition protects
β-islet cells by increased acetylation of proteins [14]. Indeed, if lysine deacetylase inhibitors
are brought forward to humans, their impact might be greater in early-onset diabetic subjects
by conferring a presumed β-islet cell protective factor and restoring acetyllysine levels to
higher levels.
Eicosapentaenoate (EPA), a metabolite of the polyunsaturated fatty acid metabolic pathway,
was lower in early-onset type 1 diabetes and high in late-onset diabetics even exceeding the
levels of control populations. Several studies support the concept that EPA improves insulin
secretion in pancreatic islets [15, 16]. Since we found that EPA is lower in early-onset diabetes
compared to late-onset diabetics, this again supports a more rapid disease progression in such
individuals. It also suggests late-onset diabetic subjects could make EPA as a protective factor.
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Figure 5. The over- and under-expression of metabolites associated with early- and late-onset diabetes. Shown is the
ratio of metabolites in early- versus late-onset. For clarity, ratios between 0 and 1 were inverted (1/ratio) and made neg-
ative. Data are presented as rank order based on the magnitude of the statistically significant metabolic trends. Both
sample sets demonstrate the tight reproducibility in the direction of the trends and also in the reproducibility of the
magnitude of the derangements between early- and late-onset type 1 diabetics.
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Metabolite Pathway    Ratio early/
late (average
of both
screens) 
Association with diabetes   References
N2-acetyllysine Lysine metabolism 0.596 Diabetes induces lysine acetylation of
intermediary metabolism enzymes in
the kidney
Kosanam et al. [14]
Spermidine Polyamine
metabolism
0.588 Spermidine may decrease ER stress in
pancreatic beta cells and may reduce
apoptosis via activating AMPK-
dependent autophagy pathway.
Spermidine content is decreased in
islets of old obese ob/ob mice.
Polyamines such as spermidine increase
the stability of insulin mRNA and are
necessary for the maintenance of
normal insulin and protein biosynthesis
in islets
Tirupathi Pichiah et
al [36]; Sjoholm et al.
[23]; Welsh [21];
Welsh [22]
N-acetyltryptophan Tryptophan
metabolism
0.742 Suppresses rise in blood sugar and
preserves insulin secretion in type 2;
related to activity of intestinal bacteria
Wikoff et al. [17]
Glucuronate Amino sugar
metabolism
0.761 Elevated in diabetes. Glucuronate
pathway is overactive in diabetes
Winegrad and
Burden [25]
CMPF Fatty acid,
dicarboxylate
metabolism
0.152 Elevated in diabetes. Causes beta-cell
dysfunction
Nolan [26]; Prentice
et al. [27]
Eicosapentaenoate
(EPA)
Polyunsaturated
fatty
acid metabolism
0.480 Improves insulin secretion in pancreatic
islets
Kato et al. [15];
Shimano et al. [16]
Taurodeoxycholate Secondary bile acid
metabolism
0.470 Involved in regulation of exocrine
pancreas function
Riepl et al. [18]
Table 4. Early- versus late-onset diabetics: islet-, insulin-, and pancreas-related metabolites with significant differences.
N-acetyltryptophan was also observed to be lower in early-onset diabetics. N-acetyltrypto-
phan suppresses rises in blood sugars and preserves insulin secretion in type 1 diabetes [17].
Abundant n-acetyltryptophan also can be produced by select gut bacteria and modulates
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expression of proinflammatory genes and increases expression of anti-inflammatory genes
possibly affecting the etiology of both early- and late-onset diabetes [17].
Taurodeoxycholate, a metabolite related to secondary bile acid metabolism, was more de-
pressed in early-onset than late-onset diabetes. Previous evidence shows this metabolite is
involved in the regulation of exocrine pancreas function [18]. Exocrine pancreatic dysfunction
in type 1 diabetes is linked to a decrease in pancreatic volume, an observation of past reports
[19]. Therefore, our findings again point to varying contributions of pancreas defects to T1D
in early-onset subjects compared to late-onset diabetics.
Spermidine, a member of the polyamine metabolism, was decreased in early-onset diabetics
and elevated in late-onset subjects. Past reports suggest type 1 diabetic subjects have reduced
spermidine levels, and now our data suggests this deficiency is even more pronounced in early-
onset diabetes [20]. Spermidine may decrease endoplasmic reticulum (ER) stress in pancreatic
islet beta cells, is decreased in islets of obese-hyperglycemic ob/ob mice, and is also reported
to reduce apoptosis via AMP-activated protein kinase (AMPK)-dependent autophagy
pathways [21–24]. A deficiency in spermidine might accelerate disease onset.
Glucuronate, which was also lower in early-onset diabetes, is involved in amino sugar
metabolism. Some reports characterize this metabolite as related to diabetic hyperglycemia
[25]. Again this points to altered and varying levels between early- and late-onset subjects.
Lastly, the metabolite 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid (CMPF) was high
in late-onset diabetic subjects and very low in early-onset diabetics and control subjects had
intermediate levels. CMPF is associated with pancreatic function. This metabolite causes β-
islet cell dysfunction when elevated [26, 27]; CMPF is part of the fatty acid and decarboxylase
metabolism pathway. Here, the elevation in CMPF is restricted to late-onset disease compared
to early-onset disease, where the levels are actually suppressed in early-onset diabetics
compared to control populations (data not shown). This pancreas-related metabolite was the
exception between early- and late-onset subjects since in all other six cases the early-onset
subject demonstrated the more pronounced defect.
Is there evidence to support the hypothesis that intrinsic pancreas defects unrelated to the
immune system contribute to a broader etiologic basis of diabetes, perhaps related to the target
organ? Developmental biology has long been ignored in the etiology of autoimmune diseases
[28, 29]. In the NOD mouse, there is both support for direct T-cell-driven autoimmunity and
secondary organ failure from intrinsic developmental defects. Using NOD-scid mice without
an immune system, NOD structural defects related to organogenesis can be observed in the
pancreas and salivary glands from birth onward and in other organs. The structurally defective
organs share a common developmentally related origin: Hox11-expressing progenitor cells
during fetal development [29]. Hox11-derived organs such as the cochlea/inner ear are related
to Hox11 developmental biology, as are the sensory portions of the tongue. NOD mice fail to
form an inner ear and are born deaf; they also have malformed sensory end organs of the
tongue [28]. The human evidence provided here by metabolomics offers additional support
for the possibility that intrinsic pancreas developmental defects could contribute, at least in
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early-onset human diabetes, to more rapid end-organ failure as has been shown in the NOD
mouse.
In conclusion, there is supporting evidence from both autoimmune mice and humans that
primary, not secondary, additional pancreas dysfunction in diabetes could be driven by
developmental biology defects and that associated organs can also fail even without a
lymphocyte influence.
5. Implications for therapy
What are the therapeutic implications of the pathophysiological differences underlying early-
and late-onset diabetes? For early-onset diabetics, their rapid deficiency in autoreactive T-cells
suggests that they are unlikely to respond to immunotherapy aimed at abolishing the auto-
immune response if the therapy is started very long after the disease onset. Conversely, for
late-onset diabetics, immunotherapies are likely to be effective longer because the patients still
have a vigorous autoimmune response and in many cases pancreatic insulin secretion that
could be reserved.
The first hint that immunotherapies may be preferentially effective for late-onset diabetes came
from a phase I, proof-of-concept clinical trial, published by our laboratory in 2012. It was found
that the immunotherapy bacillus Calmette-Guérin (BCG) transiently dampens autoimmunity
by selective targeting for death autoreactive T-cells and inducing the beneficial T-regulatory
T-cells. With BCG, patients with long-standing disease (mean duration of 15.3 years) fleetingly
produced higher levels of C-peptide, showed increases in dead autoreactive T-cells, and
produced more T-regulatory cells (Tregs) that suppress autoimmunity. When all weekly blood
sera were analyzed by an ultrasensitive assay at the end of the trial, all BCG recipients (as well
as placebo controls) were found to have low yet detectable C-peptide secretion.
BCG’s apparent efficacy in type 1 diabetes stems from its induction of endogenous tumor
necrosis factor (TNF)-α [30], which, in turn, selectively kills CD8+, but not CD4+, autoreactive
T-cells in type 1 diabetics and other autoimmune diseases [31]. TNF is also known to expand
T-regulatory T-cells as well. TNF itself is not a suitable exogenous immunotherapy because of
its high toxicity, which is largely due to widespread expression of the TNF receptor 1 [32]. The
TNF inducer BCG is a safer alternative to direct administration of TNF.
BCG is also advantageous because of its FDA approval, low cost, and its 100-year track record
of safety as a tuberculosis vaccine and 40-year track record of safety as a treatment for bladder
cancer. The BCG trial was among the first immunotherapy clinical trials to include long-
standing diabetic subjects, as most if not all of immunotherapy trials over the past 20 years
have excluded all but new-onset patients under the now erroneous assumption that β-islets
are not salvageable.
A phase II clinical trial of BCG is now in progress, using more frequent doses, a larger group
of subjects (n = 150), and a 5-year follow-up. The primary objective of this randomized, placebo-
controlled double-blind trial is to determine the dose and timing of BCG administration
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necessary to trigger a significant improvement in HbA1c values. One of the inclusion criteria
is that subjects have fasting or stimulated C-peptide levels between 5 and 200 pmol/L, because
these levels are indicative of remaining pancreatic islet function. With the additional criteria
that these subjects also must be adults (greater than age 18), the majority of the subjects will
also be late-onset subjects.
Two other recent immunotherapy clinical trials in type 1 diabetes, using abatacept and
teplizumab, have had disappointing results [33, 34]. One reason postulated to be behind the
lackluster results was the heterogeneity of type 1 diabetics, including age of onset [35]. We
agree that early- versus late-onset might have been one important source of disease heteroge-
neity that hampered the trials’ success. The results of our BCG trial and the data we have
presented here on C-peptide persistence and age of onset suggest that immunotherapy clinical
trials no longer exclude all but new-onset cases.
In conclusion, the data that we report here reveal that early- and late-onset diabetics differ in
terms of C-peptide production, autoreactive T-cell levels, and metabolites. Taken together, the
data suggests that therapies aimed at immune defects are likely to have greater efficacy in late-
onset diabetes, whereas therapies aimed at immune defects and β-islet preservation are likely
to have greater efficacy in early-onset diabetes.
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